This Week in Psychedelics

MDMA cures PTSD in 72% of test subjects; Buckley Waves secures massive funding round; California lawmakers decriminalize mushrooms.

September 15, 2023

This Week...

Nature Medicine published the peer-reviewed results of MAPP2, the second Phase 3 trial of MDMA-assisted therapy for PTSD.  

While nothing is 100% effective, by the study’s end 72% of people in the MDMA group no longer met the diagnostic criteria for PTSD. This is huge!

This research is the final trial conducted by MAPS, which will now submit the results as part of an application to the Food and Drug Administration for approval to market MDMA as a supplement for talk therapy. Check it out:

Beckley Waves, a venture studio that invests in the psychedelics ecosystem, announced that it closed a $3.3 million funding round. Proceeds will be used to build and invest in startups that provide the infrastructure and services necessary for expanding safe and legal access to psychedelic therapies across the globe. Here’s more:

The Beckley Foundation and Maastricht University released new research that indicates psilocybin can rapidly and persistently reduce harmful inflammatory markers associated with stress-related disorders like depression, anxiety, and PTSD. Check it out:

Did You Know?

Did you know that California lawmakers recently passed a proposal to decriminalize the use of plant-based psychedelic drugs including magic mushrooms?

Governor Gavin Newsom now has until October 14th to sign or veto the bill. If he signs it, the law would go into effect at the start of 2025, and make California the third state to decriminalize plant-based psychedelics. Here's more: